United States of America

United States of America

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
0.34 (0.30 - 0.38) 2019 Modelled IHME
0.34 (0.30 - 0.38) 2018 Modelled IHME
0.34 (0.30 - 0.39) 2017 Modelled IHME
0.35 (0.31 - 0.39) 2016 Modelled IHME
0.36 (0.32 - 0.41) 2015 Modelled IHME
0.37 (0.33 - 0.42) 2014 Modelled IHME
0.38 (0.33 - 0.42) 2013 Modelled IHME
0.38 (0.34 - 0.43) 2012 Modelled IHME
0.39 (0.34 - 0.44) 2011 Modelled IHME
0.4 (0.35 - 0.45) 2010 Modelled IHME
0.41 (0.36 - 0.46) 2009 Modelled IHME
0.42 (0.37 - 0.47) 2008 Modelled IHME
0.43 (0.37 - 0.48) 2007 Modelled IHME
0.44 (0.38 - 0.49) 2006 Modelled IHME
0.44 (0.39 - 0.50) 2005 Modelled IHME
0.45 (0.39 - 0.51) 2004 Modelled IHME
0.45 (0.40 - 0.51) 2003 Modelled IHME
0.46 (0.40 - 0.52) 2002 Modelled IHME
0.46 (0.40 - 0.52) 2001 Modelled IHME
0.47 (0.41 - 0.52) 2000 Modelled IHME
0.47 (0.41 - 0.53) 1999 Modelled IHME
0.48 (0.42 - 0.54) 1998 Modelled IHME
0.49 (0.42 - 0.55) 1997 Modelled IHME
0.49 (0.43 - 0.56) 1996 Modelled IHME
0.5 (0.43 - 0.56) 1995 Modelled IHME
0.5 (0.44 - 0.57) 1994 Modelled IHME
0.51 (0.44 - 0.58) 1993 Modelled IHME
0.51 (0.45 - 0.58) 1992 Modelled IHME
0.52 (0.45 - 0.59) 1991 Modelled IHME
0.52 (0.45 - 0.59) 1990 Modelled IHME
0.38 (0.29 - 0.49) 1994 Survey/reported Wasley A et al, 2010
0.27 (0.20 - 0.35) 2006 Survey/reported Wasley A et al, 2010
0.3 (0.20 - 0.40) 2012 Survey/reported Roberts H et al, 2016
0.23 (0.18 - 0.28) 2015 Modelled WHO
0.27 (0.24 - 0.30) 2013 Modelled Schweitzer et al, 2015
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.03 (0.02 - 0.04) 2019 Modelled IHME
0.03 (0.02 - 0.04) 2018 Modelled IHME
0.03 (0.02 - 0.04) 2017 Modelled IHME
0.03 (0.02 - 0.04) 2016 Modelled IHME
0.03 (0.02 - 0.04) 2015 Modelled IHME
0.03 (0.02 - 0.04) 2014 Modelled IHME
0.03 (0.03 - 0.04) 2013 Modelled IHME
0.03 (0.03 - 0.04) 2012 Modelled IHME
0.04 (0.03 - 0.04) 2011 Modelled IHME
0.04 (0.03 - 0.04) 2010 Modelled IHME
0.03 (0.03 - 0.04) 2009 Modelled IHME
0.03 (0.03 - 0.04) 2008 Modelled IHME
0.03 (0.02 - 0.04) 2007 Modelled IHME
0.03 (0.02 - 0.04) 2006 Modelled IHME
0.03 (0.02 - 0.04) 2005 Modelled IHME
0.03 (0.02 - 0.04) 2004 Modelled IHME
0.03 (0.02 - 0.04) 2003 Modelled IHME
0.03 (0.03 - 0.04) 2002 Modelled IHME
0.04 (0.03 - 0.05) 2001 Modelled IHME
0.04 (0.03 - 0.05) 2000 Modelled IHME
0.04 (0.03 - 0.05) 1999 Modelled IHME
0.04 (0.03 - 0.05) 1998 Modelled IHME
0.04 (0.03 - 0.06) 1997 Modelled IHME
0.05 (0.04 - 0.06) 1996 Modelled IHME
0.05 (0.04 - 0.07) 1995 Modelled IHME
0.06 (0.04 - 0.08) 1994 Modelled IHME
0.07 (0.05 - 0.09) 1993 Modelled IHME
0.09 (0.07 - 0.11) 1992 Modelled IHME
0.11 (0.08 - 0.13) 1991 Modelled IHME
0.13 (0.10 - 0.16) 1990 Modelled IHME
0.04 (0.03 - 0.05) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
12 (10 - 14) 2019 Modelled IHME
12 (10 - 14) 2018 Modelled IHME
12 (10 - 14) 2017 Modelled IHME
12 (10 - 14) 2016 Modelled IHME
12 (10 - 14) 2015 Modelled IHME
12 (11 - 14) 2014 Modelled IHME
12 (11 - 14) 2013 Modelled IHME
12 (11 - 14) 2012 Modelled IHME
12 (11 - 14) 2011 Modelled IHME
12 (11 - 14) 2010 Modelled IHME
13 (11 - 14) 2009 Modelled IHME
13 (11 - 14) 2008 Modelled IHME
13 (11 - 14) 2007 Modelled IHME
13 (11 - 15) 2006 Modelled IHME
13 (11 - 15) 2005 Modelled IHME
13 (12 - 15) 2004 Modelled IHME
13 (12 - 15) 2003 Modelled IHME
13 (12 - 15) 2002 Modelled IHME
13 (12 - 15) 2001 Modelled IHME
13 (12 - 15) 2000 Modelled IHME
13 (12 - 14) 1999 Modelled IHME
13 (11 - 14) 1998 Modelled IHME
13 (11 - 14) 1997 Modelled IHME
13 (11 - 14) 1996 Modelled IHME
13 (11 - 14) 1995 Modelled IHME
13 (11 - 14) 1994 Modelled IHME
13 (11 - 14) 1993 Modelled IHME
13 (11 - 15) 1992 Modelled IHME
13 (11 - 15) 1991 Modelled IHME
13 (11 - 15) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
66 2018 Survey/reported WHO/UNICEF
64 2017 Survey/reported WHO/UNICEF
64 2016 Survey/reported WHO/UNICEF
72 2015 Survey/reported WHO/UNICEF
72 2014 Survey/reported WHO/UNICEF
74 2013 Survey/reported WHO/UNICEF
72 2012 Survey/reported WHO/UNICEF
69 2011 Survey/reported WHO/UNICEF
64 2010 Survey/reported WHO/UNICEF
61 2009 Survey/reported WHO/UNICEF
55 2008 Survey/reported WHO/UNICEF
53 2007 Survey/reported WHO/UNICEF
50 2006 Survey/reported WHO/UNICEF
50 2005 Survey/reported WHO/UNICEF
48 2004 Survey/reported WHO/UNICEF
39 2003 Survey/reported WHO/UNICEF
21 2002 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
91 2018 Survey/reported WHO/UNICEF
93 2017 Survey/reported WHO/UNICEF
93 2016 Survey/reported WHO/UNICEF
92 2015 Survey/reported WHO/UNICEF
92 2014 Survey/reported WHO/UNICEF
91 2013 Survey/reported WHO/UNICEF
90 2012 Survey/reported WHO/UNICEF
91 2011 Survey/reported WHO/UNICEF
92 2010 Survey/reported WHO/UNICEF
92 2009 Survey/reported WHO/UNICEF
94 2008 Survey/reported WHO/UNICEF
93 2007 Survey/reported WHO/UNICEF
93 2006 Survey/reported WHO/UNICEF
93 2005 Survey/reported WHO/UNICEF
92 2004 Survey/reported WHO/UNICEF
92 2003 Survey/reported WHO/UNICEF
88 2002 Survey/reported WHO/UNICEF
89 2001 Survey/reported WHO/UNICEF
90 2000 Survey/reported WHO/UNICEF
88 1999 Survey/reported WHO/UNICEF
87 1998 Survey/reported WHO/UNICEF
84 1997 Survey/reported WHO/UNICEF
82 1996 Survey/reported WHO/UNICEF
68 1995 Survey/reported WHO/UNICEF
42 1994 Survey/reported WHO/UNICEF
16 1993 Survey/reported WHO/UNICEF
Showing out of
Show more

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
30 (11 - 49) 2016 Survey/reported NASEN, 2015; Wejnert C et al, 2016; Des Jarlais D et al , 2013
HBV National Action Plan
HBV elimination goal
HBV testing policy
Pregnant women, Risk-based
HepB birth dose policy
Yes
Year of birth dose introduction
1999
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
HCV testing policy
Universal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
1.18 (0.95 - 1.45) 2019 Modelled IHME
1.18 (0.96 - 1.45) 2018 Modelled IHME
1.18 (0.96 - 1.45) 2017 Modelled IHME
1.15 (0.94 - 1.41) 2016 Modelled IHME
1.12 (0.91 - 1.38) 2015 Modelled IHME
1.12 (0.91 - 1.37) 2014 Modelled IHME
1.11 (0.90 - 1.36) 2013 Modelled IHME
1.1 (0.90 - 1.36) 2012 Modelled IHME
1.1 (0.89 - 1.36) 2011 Modelled IHME
1.1 (0.89 - 1.36) 2010 Modelled IHME
1.11 (0.90 - 1.37) 2009 Modelled IHME
1.12 (0.90 - 1.38) 2008 Modelled IHME
1.13 (0.91 - 1.40) 2007 Modelled IHME
1.14 (0.92 - 1.41) 2006 Modelled IHME
1.14 (0.92 - 1.42) 2005 Modelled IHME
1.14 (0.92 - 1.42) 2004 Modelled IHME
1.14 (0.92 - 1.41) 2003 Modelled IHME
1.14 (0.92 - 1.41) 2002 Modelled IHME
1.14 (0.92 - 1.41) 2001 Modelled IHME
1.14 (0.92 - 1.41) 2000 Modelled IHME
1.13 (0.91 - 1.40) 1999 Modelled IHME
1.11 (0.89 - 1.38) 1998 Modelled IHME
1.08 (0.87 - 1.34) 1997 Modelled IHME
1.06 (0.85 - 1.31) 1996 Modelled IHME
1.04 (0.83 - 1.29) 1995 Modelled IHME
1.02 (0.82 - 1.27) 1994 Modelled IHME
1.01 (0.81 - 1.26) 1993 Modelled IHME
1 (0.81 - 1.25) 1992 Modelled IHME
0.99 (0.80 - 1.24) 1991 Modelled IHME
0.99 (0.79 - 1.23) 1990 Modelled IHME
1 (0.80 - 1.10) 2016 Survey/reported Hofmeister MG et al, 2019 (Adjusted)
1 (0.80 - 1.20) 2010 Survey/reported Denniston MM et al, 2014 (Unadjusted)
1.3 (1 - 1.50) 2002 Survey/reported Armstrong GL wt al, 2006 (Unadjusted)
1 (0.90 - 1.80) 2014 Modelled Gower et al, 2014
0.84 (0.75 - 0.96) 2016 Survey/reported Rosenberg et al, 2018 (Unadjusted)
0.93 2016 Survey/reported Rosenberg et al, 2018 (Adjusted)
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
1.7 (1.40 - 2) 2016 Survey/reported Hofmeister MG et al, 2019 (Adjusted)
1.3 (1.20 - 1.50) 2010 Survey/reported Denniston MM et al, 2014 (Unadjusted)
1.6 (1.30 - 1.90) 2002 Survey/reported Armstrong GL wt al, 2006 (Unadjusted)
1.8 (1.50 - 2.30) 1994 Survey/reported Alter MJ et al, 1999 (Unadjusted)
1.3 (1.20 - 2.40) 2014 Modelled Gower et al, 2014
1.9 (1.50 - 2.50) 2002 Survey/reported Ditah et al, 2014
1.3 (0.90 - 1.80) 2006 Survey/reported Ditah et al, 2014
Showing out of
Show more
People who inject drugs (PWID)
Download
Value (%) Year Type Source
53.1 (38.10 - 68) 2016 Modelled Degenhardt L et al, 2017

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
39 (35 - 43) 2019 Modelled IHME
39 (35 - 43) 2018 Modelled IHME
39 (35 - 43) 2017 Modelled IHME
40 (36 - 44) 2016 Modelled IHME
41 (37 - 44) 2015 Modelled IHME
41 (37 - 44) 2014 Modelled IHME
41 (37 - 44) 2013 Modelled IHME
41 (37 - 44) 2012 Modelled IHME
40 (37 - 44) 2011 Modelled IHME
40 (37 - 44) 2010 Modelled IHME
40 (37 - 43) 2009 Modelled IHME
40 (37 - 43) 2008 Modelled IHME
40 (37 - 43) 2007 Modelled IHME
40 (37 - 42) 2006 Modelled IHME
39 (36 - 42) 2005 Modelled IHME
39 (36 - 42) 2004 Modelled IHME
39 (36 - 42) 2003 Modelled IHME
39 (36 - 42) 2002 Modelled IHME
39 (36 - 42) 2001 Modelled IHME
39 (36 - 42) 2000 Modelled IHME
39 (36 - 42) 1999 Modelled IHME
39 (36 - 42) 1998 Modelled IHME
39 (36 - 42) 1997 Modelled IHME
39 (36 - 42) 1996 Modelled IHME
39 (35 - 42) 1995 Modelled IHME
38 (35 - 42) 1994 Modelled IHME
38 (35 - 42) 1993 Modelled IHME
38 (35 - 41) 1992 Modelled IHME
38 (35 - 41) 1991 Modelled IHME
38 (34 - 41) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)
Download
Value Year Type Source
300 (11 - 49) 2016 Survey/reported NASEN, 2015; Wejnert C et al, 2016; Des Jarlais D et al , 2013
HBV National Action Plan
HBV elimination goal
HBV testing policy
Pregnant women, Risk-based
HepB birth dose policy
Yes
Year of birth dose introduction
1999
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
HCV testing policy
Universal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
0.34 (%)
2019
(0.3 - 0.38(%))
IHME
HCV (RNA/cAg+)
1.18 (%)
2019
(0.95 - 1.45(%))
IHME

Survey/surveillance

HBV (HBsAg+)
0.3 (%)
2012
(0.2 - 0.4(%))
Roberts H et al, 2016
HCV (anti-HCV)
1.7 (%)
2016
(1.4 - 2(%))
Hofmeister MG et al, 2019 (Adjusted)

Hepatitis related deaths (national)

Modelled

HBV
4,486
2019
(3,874 - 5,178)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
39,158
2019
(35,520 - 43,124)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.03 (%)
2019, latest modelled
(0.02 - 0.04(%))
IHME

Prevalence PWID

HCV
53.10 (%)
2016, latest modelled
(38.10 - 68(%))
Degenhardt L et al, 2017

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
66 (%)
2018
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

HCV
30
2016
(11 - 49)
NASEN, 2015; Wejnert C et al, 2016; Des Jarlais D et al , 2013
Eligible for HBV generic medicines
Eligible for HCV generic medicines

Action plans

Resources